BCR-ABL1 G250E
|
ALL
|
BCR-ABL1 G250E
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 G250E
|
CML
|
BCR-ABL1 G250E
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 G250E
|
ALL
|
BCR-ABL1 G250E
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 G250E
|
CML
|
BCR-ABL1 G250E
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 G250E
|
CML
|
BCR-ABL1 G250E
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 G250E
|
CML
|
BCR-ABL1 G250E
|
CML
|
nilotinib Resistant: D – Preclinical
|
nilotinib Resistant: D – Preclinical
|